Tisotumab Vedotin in Cervical Cancer

Tisotumab vedotin is discussed as an important therapeutic step forward for recurrent or metastatic cervical cancer because it offers clinically meaningful activity in a setting where later line treatment has often been disappointing. The faculty reflect on an earlier era when nonplatinum therapy produced limited responses and few durable options after progression, making newer agents especially valuable. Confirmatory phase 3 data comparing tisotumab vedotin with investigator choice chemotherapy are presented as a key reason clinicians now view the drug with greater confidence. At the same time, successful use depends on more than efficacy data alone. The panel underscores the importance of toxicity prevention, patient counseling, and close follow up so that adverse events can be addressed before they force treatment interruption. Ocular toxicity, neuropathy, and bleeding risk all require active management. The overall perspective is that tisotumab vedotin represents a genuine improvement in care, but one whose benefit is closely tied to clinician familiarity, supportive care planning, and the ability to keep patients on therapy safely.